10x Genomics, Inc. (TXG) Guidance & Earnings Results
On 2026-08-06 10x Genomics, Inc. raised guidance: "Revenue guidance raised from $600M-$625M to…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TXG10x Genomics, Inc.Follow TXG — free
—
Price chart with a free account
- Market cap
- 9.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 6 Aug 26 | Raised | Revenue guidance raised from $600M-$625M to $610M-$630M · full year |
| 7 May 26 | Reaffirmed | FY2026 revenue $600-625M · full year |
| 12 Feb 26 | Lowered | FY26 revenue guidance $600-625M, implying 0-4% growth ex-litigation vs FY25 core decline of 2% |
| 6 Nov 25 | Lowered | Q4 2025 revenue $154-158M, -6% YoY |
| 7 Aug 25 | Lowered | Q3 2025 revenue guidance $140-144M; implies sequential decline from Q2 ex-settlement ($145.6M) and core decline YoY |
10x Genomics, Inc. — questions
- What guidance did 10x Genomics, Inc. give?
- On 2026-08-06: "Revenue guidance raised from $600M-$625M to $610M-$630M"
- When does 10x Genomics, Inc. report earnings?
- 10x Genomics, Inc.'s next earnings report is expected on 2026-11-05.
Every figure on this page comes from 10x Genomics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.